Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix long-term extension study in prostate cancer
NL-OMON31249Phase 3Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Changes in clinical safety parameters and Clinically significant changes in laboratory safety parameters. Started Jul 2007; status: active, not recruiting.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON31249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31249.